A trial comparing the efficacy and tolerability of Faslodex with Nolvadex in postmenopausal women with advanced breast cancer
Study identifier:9238IL/0025
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A double-blind, randomized, multicentre trial comparing the efficacy and tolerability of 250mg of Faslodex (long acting ICI 182,780) with 20mg of Nolvadex (Tamoxifen) in postmenopausal women with advanced breast cancer
Medical condition
Breast Cancer
Phase
Phase 3
Healthy volunteers
No
Study drug
Fulvestrant, Tamoxifen
Sex
Female
Actual Enrollment
51
Study type
Interventional
Age
N/A
Date
Study Start Date: 01 Nov 1998
Primary Completion Date: 01 Mar 2007
Study Completion Date: 01 Jan 2012
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1 Tamoxifen | Drug: Tamoxifen 20 mg oral tablet Other Name: Nolvadex |
| Experimental: 2 Fulvestrant | Drug: Fulvestrant intramuscular injection 250 mg Other Name: Faslodex Other Name: ZD9238 |
Contacts
Investigators
Principal Investigator
AstraZeneca Oncology Medical Science Director
AstraZeneca
